CagriSema Tracker - Side Effects, Food, Weight | MeAgain

CagriSema Tracker App for Side Effects, Food, and Weight

MeAgain is a CagriSema tracker for the record you can build now: current medication, shot day, side effects, food, water, and weight trend. CagriSema combines cagrilintide and semaglutide in one weekly pen, which is why people describe it as two drugs in one pen rather than a single new molecule. As of July 2026, CagriSema is not FDA-approved. Novo Nordisk submitted an FDA application in December 2025 and has guided to a possible decision in late 2026, but that is company guidance, not a confirmed FDA date. While waiting or taking part in a Novo study, the useful habit is still simple: track what you are currently using, record stomach and digestion symptoms, keep food and water visible, and follow the long weight trend. If a new medication arrives later, your MeAgain history carries over. 807K users already use MeAgain, with 4.8 stars across 37K App Store ratings.

Start Tracking CagriSema See CagriSema Tracking Tools

Published by·MeAgain·GLP-1 tracker·Sources checkedJuly 5, 2026

807K People tracking GLP-1
4.8★ / 37K App Store ratings
iPhone + Android App Store + Google Play
All-in-one tracker Shots · food · symptoms · weight

Key takeaways

  1. CagriSema is best described as two drugs in one weekly pen: cagrilintide plus semaglutide. That matters for tracking because the routine still looks familiar day to day: shot day, side effects, meals, water, and the long weight trend.
  2. CagriSema has no FDA approval as of July 2026. Novo filed its application in December 2025 and points investors to a possible late-2026 decision - guidance, not a scheduled date.
  3. The pivotal REDEFINE results are the main reason people are searching CagriSema. REDEFINE 1 reported 22.7% mean weight loss in adults without diabetes, while REDEFINE 2 reported 13.7% in adults with type 2 diabetes. Both were published in NEJM.
  4. CagriSema did not beat Zepbound in the REDEFINE 4 head-to-head trial. Novo reported 23.0% weight loss for CagriSema versus 25.5% for Zepbound, and the trial did not meet its primary goal.
  5. MeAgain is useful now because the tracking habit does not have to wait for approval. Track your current medication, side effects, food, water, and weight trend; if a new medication arrives later, that history carries over.

What Makes MeAgain the Right CagriSema Tracker?

  1. A Weekly Shot Log for the Routine Around CagriSema

CagriSema is not publicly available yet, but the weekly routine people want to understand is already clear enough to track. MeAgain lets you save the medication you are using now, the date and time of each shot, and the shot site on a body diagram. That makes the record useful whether you are following CagriSema research, taking part in a Novo study, or using another weekly GLP-1 while you wait. The important part is continuity. If your medication changes later, your shot history, side effect notes, food logs, and weight trend stay in one place instead of starting over from a blank timeline. It also gives you cleaner context for appointments because the week is recorded as it happened, not reconstructed from memory.

  1. Side Effect Tracking for Stomach and Digestion Symptoms

Novo described CagriSema side effects in the pivotal trials as mainly stomach and digestion problems, including nausea, vomiting, diarrhea, and constipation. MeAgain turns that broad list into a week-by-week record. You can log common GLP-1 side effects, add custom symptoms, score how strong they felt, and attach notes about meals, hydration, or timing. That matters because a symptom that feels random in the moment can make more sense when it sits next to shot day, a low-food day, or a change in routine. If you are in a study, that kind of clean symptom timeline is also easier to discuss with a clinician than a few scattered notes. The goal is not to guess what caused a symptom; it is to keep the pattern visible.

  1. Food, Water, and Weight Trends While You Wait

CagriSema headlines focus on trial percentages, but the day-to-day work is smaller: eating enough protein, drinking enough water, and not overreacting to one weigh-in. MeAgain keeps meals, water, side effects, and weight in the same timeline so you can see what happened before a rough day or a surprising scale change. Food logging is built to stay quick with photo scan, barcode scan, voice dictation, text search, and quick-add for repeat meals. The weight chart keeps the long view visible, which is the part that matters most for medications studied over many months. That longer view is also useful while waiting because your current habits become the baseline for any future change. It keeps current-med context beside the future CagriSema question.

  1. A History That Carries Over if New Meds Arrive

The strongest reason to start tracking before CagriSema approval is that your history becomes more valuable over time. If you are using semaglutide, tirzepatide, or another current medication today, MeAgain can keep the same practical record CagriSema would need later: current medication, shot dates, side effects, meals, water, and weight. When new medications reach real-world use, the question is rarely just which name is on the box. It is what changed in your routine, symptoms, appetite, and trend. A continuous MeAgain timeline gives you that before-and-after view without asking you to rebuild your records. It also keeps the waiting period productive because each week adds context instead of another loose note. That continuity is the point of tracking before approval.

What to Know About CagriSema Availability and Tracking

CagriSema remains experimental and trial-only as of July 2026. The FDA application, filed in December 2025, rests on REDEFINE 1 and REDEFINE 2; Novo's own investor guidance points to a possible decision in late 2026, and no confirmed FDA date exists. The main published trial results are REDEFINE 1, which reported 22.7% mean weight loss over 68 weeks in adults without diabetes, and REDEFINE 2, which reported 13.7% over 68 weeks in adults with type 2 diabetes. If you compare CagriSema with Zepbound, the plain fact is that REDEFINE 4 reported CagriSema 23.0% versus Zepbound 25.5%, and CagriSema did not meet its head-to-head goal. MeAgain gives you the tracker for the part you can use now: current medication, side effects, food, water, and the long weight trend.

CagriSema Tirzepatide / Zepbound Semaglutide / Wegovy
Current U.S. status Trial-only, not FDA-approved FDA-approved FDA-approved
How often taken Weekly pen Weekly shot Weekly shot
Sourced trial weight results 22.7% in REDEFINE 1; 13.7% in REDEFINE 2 20.9% in 72 weeks (SURMOUNT-1) 14.9% in 68 weeks (STEP-1)
Head-to-head context Lost REDEFINE 4: 23.0% vs 25.5% for Zepbound 25.5% in REDEFINE 4 No CagriSema head-to-head result on this page
What MeAgain helps you track Current med, side effects, food, weight trend Current med, side effects, food, weight trend Current med, side effects, food, weight trend

CagriSema Facts to Know Right Now

CagriSema may still be trial-only, but the habits around GLP-1 tracking are useful now. MeAgain keeps your current medication, shot history, side effects, food, water, and weight trend in one place so the record is ready if your medication changes later.
This content is for informational purposes only and does not constitute medical advice. As of July 2026, CagriSema is experimental, in clinical trials, and not FDA-approved for any use. Published CagriSema results may change as more Phase 3 data are released. Always talk with a licensed clinician about CagriSema, weekly GLP-1 treatment, or weight-management medication. MeAgain is not affiliated with Novo Nordisk and does not enroll people in CagriSema trials.